



August 8, 2017

## **AGTC to Present at the Webbush PacGrow Healthcare Conference on August 16, 2017**

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation ([AGTC](#)), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President and Chief Executive Officer, will present at the Webbush PacGrow Healthcare Conference on Wednesday, August 16, 2017 at 9:45am ET in New York.

AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments.

AGTC's pipeline includes ophthalmology programs in X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia caused by mutations in the CNGB3 and CNGA3 genes, wet age-related macular degeneration and an optogenetics program with Bionic Sight.

A live audio webcast of the presentation will be accessible by visiting [ir.agtc.com/events.cfm](http://ir.agtc.com/events.cfm). A replay will be available on the company's website following the event.

### **About AGTC**

AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's product pipeline includes ophthalmology programs in X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet age-related macular degeneration, and an optogenetics program with Bionic Sight. AGTC's non-ophthalmology programs include its adrenoleukodystrophy program and its otology program, which is in pre-clinical development, and the company expects to advance several otology product candidates into clinical development in the next few years. Each of AGTC's XLRS, XLRP and adrenoleukodystrophy programs are part of its collaboration and license agreement with Biogen. AGTC employs a highly-targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need that it believes are clinically feasible and present commercial opportunities. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products.

### **Contact:**

#### IR/PR CONTACTS:

David Carey (IR)  
Lazar Partners Ltd.  
T: (212) 867-1768  
[dcarey@lazarpartners.com](mailto:dcarey@lazarpartners.com)

#### Corporate Contacts:

Stephen Potter  
Chief Business Officer  
Applied Genetic Technologies Corporation  
T: (617) 413-2754  
[spotter@agtc.com](mailto:spotter@agtc.com)